Navigation Links
First description of a triple DNA helix in a vacuum
Date:4/18/2012

A team of researchers at the Institute for Research in Biomedicine (IRB Barcelona) and the Barcelona Supercomputing Center (BSC) have managed for the first time to extract trustworthy structural information from a triple helix DNA in gas phase, that is to say in conditions in which DNA is practically in a vacuum. The study appears today in the Journal of the American Chemical Society (JACS), one of the journals with greatest impact in chemistry.

"Until now these special DNA structures were almost impossible to detect and it was not known whether they preserved structural memory in solution when they were evaporated. With this study we have characterized this structure and demonstrated that it maintains a surprising memory of its previous biological environment, aqueous solution, in which it is normally very difficult to characterize", explains Modesto Orozco, principal investigator at IRB Barcelona, senior professor at the University of Barcelona and director of Life Sciences at the BSC. Orozco's team has combined computational simulation techniques with experimental validation through mass spectrometry. This was the last structure pending to complete the atlas of classical DNA structures in gas phase, work that has taken Dr. Orozco's group more than ten years of dedication.

A step towards antigen therapy

One of the most relevant biomedical consequences of this study is that it could avail the development of the so-called antigen therapy. This therapeutic approach, which is based on DNA triple helix structures, would switch off the activity of the genes involved in a given disease. "There is still no drug based on gene therapy in the market but several are under development", explains the researcher. One of the main obstacles blocking the availability of these therapies was in the difficulty to experimentally detect these triple helix structures. "Demonstration that the structure is maintained in gas phase will allow these DNA structures to be detected more easily", affirms Dr. Orozco.

Shedding light on biological molecules

Furthermore, these results pave the way for the implementation of new structural resolution techniques based on the use of x-ray free-electron lasers (X-FEL). The X-FEL is a large scientific facility being built in Germany that produces intense light pulses, similar to a synchrotron. "If our calculations are correct X-FEL could be used to obtain structural data in gas phase about the behavior of a molecule in its natural biological environment and X-FEL would become a very powerful tool to resolve the structure of macromolecules", Orozco goes on to say.

Computational simulation has been performed using the supercomputer MareNostrum at the BSC while the experimental validation has been undertaken by the Mass Spectrometry Core Facility at IRB Barcelona, the Experimental Bioinformatics Lab (EBL) a joint IRB Barcelona and BSC facility-, and with the collaboration of Valerie Gabelica's group at the University of Lige, Belgium.


'/>"/>

Contact: Sonia Armengou
sonia.armengou@irbbarcelona.org
34-934-037-255
Institute for Research in Biomedicine (IRB Barcelona)
Source:Eurekalert  

Related biology news :

1. New way to make malaria medicine also first step in finding new antibiotics
2. Complete Genomics launches, becomes worlds first large-scale human genome sequencing company
3. Digital zebrafish embryo provides the first complete developmental blueprint of a vertebrate
4. Synaptics to Report First Quarter Results on October 23
5. Alzheimers disease research attracts first partner
6. Volcanoes may have provided sparks and chemistry for first life
7. Study of polar dinosaur migration questions whether dinosaurs were truly the first great migrators
8. Synaptics Reports Record Results for First Quarter of Fiscal 2009
9. First comprehensive genomic study of common cold reveals new treatment targets
10. Scientists achieve first tracking of salmon from headwaters in Rockies through Pacific to Alaska
11. First results from hospital trials testing
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
First description of a triple DNA helix in a vacuum
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology: